about
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in Patients With Early Manifest Huntington's DiseaseCombination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast CancerVigil™ + Nivolumab in Advanced Non-Small Cell Lung CancerPhase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung CancerMasitinib in Ovarian CancerDocetaxel Followed by Provenge in Metastatic Prostate CancerBiomarkers in Urothelial Cancer Patients Treated With PembrolizumabT-Cell PET Imaging With [18F]F-AraG in Lung CancerPhase 2 Trial of Maintenance Vigil for High Risk Stage IIIb-IV Ovarian CancerA Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung CancerPembrolizumab in Advanced BRCA-mutated Breast CancerAZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung CancerAnti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast CancerStudy of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPCNivolumab With or Without Ipilimumab or Relatlimab Before Surgery in Treating Patients With Stage IIIB-IV Melanoma That Can Be Removed by SurgeryTrial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal MelanomaPegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerAtezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder CancerDaratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple MyelomaImmunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerCombination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung CancerPhase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate CancerClinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABRDurvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerEfficacy and Safety of MAA868 in Patients With Atrial FibrillationPhase II Evaluation Of Paclitaxel And Cisplatin In Combination With Split Course Hyperfractionated RadiationEfficacy of Nasal Spray Calcitonin on Recurrence of Aggressive Central Giant Cell GranulomaRadiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II StudyEfficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold GranulomasTreatment of Granuloma Umbilical in Newborn BabiesImaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary SarcoidosisPioglitazone Therapy for Chronic Granulomatous DiseaseUltraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal MatrixPlerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD PatientsCombination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGDGene Therapy for X-linked Chronic Granulomatous DiseaseGene Therapy for X-CGDGene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD)
P6099
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trialBreast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placeboLICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trialRandomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patientsPhase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast CancerOral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trialCadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trialAn open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)Phase II trial of oral aminopterin for adults and children with refractory acute leukemiaA phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaA phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerThe trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialOverall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancerClinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemiaPhase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanomaPhase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant gliomaPhase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trialResults of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritisDesign of Phase II cancer trials evaluating survival probabilitiesPISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690]Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690]Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolongPhase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma.Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewBiomarkers in phase I-II chemoprevention trials: lessons from the NCI experienceThe 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trialsStatistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trialsHeat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) - From Preclinical Studies to a Clinical Phase II TrialNovel methodologic approaches to phase I, II, and III trialsPhase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trialIntra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trialRandomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.Phase II clinical trial of sorafenib in metastatic medullary thyroid cancerPhase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
P921
Q45287449-86F4DA56-9B32-4FF4-B30E-FC7477BE3E80Q58407453-c33c93b5-498f-e050-4274-1db6befabb2eQ58407571-b7250911-4e8b-1e09-5e12-b1371ee2c26eQ58407578-042a8d66-4e44-0949-7e87-3bcefcc04cf6Q58407609-ad6e6ab8-402e-301f-b54f-d1ee66d3fad9Q58407616-f935a8ae-477f-7ad0-5d66-13bd4c0d5b87Q58407621-B5734EF0-A04E-42E3-8EC8-6F7447F21447Q58407626-2a8ab879-4b3a-a644-4c4c-618027f36c9aQ58407640-7bc59957-4fac-b55f-1570-1529fdcff93cQ58407651-6f8dd9b5-4b2c-4c63-e375-751aaa4fa1abQ58407726-41a1b47d-42d8-52ac-6713-3dd8e0fad0fcQ58407740-65E4A3C0-C426-4D64-8D7C-DF7B169D6CB5Q58407826-0ac2ff9e-4bb5-08f5-d7cd-b0cc68978be5Q58845207-a89916e6-41f8-1d07-bcd6-3df3c57d086fQ58845297-A41FA5D7-BC07-47D3-846B-C337E63217AEQ58845360-1f8879d3-40ca-cba5-804a-e4ac6629e93fQ58845470-c2b69183-4971-5220-6c4b-6e2e5e50e027Q58845627-26CCFC97-62C3-4ED9-A2EE-C7F309B54130Q58845699-AE34DA57-DAAB-4F89-9ABE-0F5E83844A60Q58847174-A374AB6B-A576-4B96-8137-46FC5CA3F374Q58849370-2B167059-0453-49A0-84C1-BE05D5AD87A0Q58849419-99DD1E8F-759A-4BCC-89B7-5872CD512CFDQ58849551-1f61584f-4c36-0983-38bc-d2931b88029bQ58849965-2423FDF1-6FF0-4C74-9411-7C194DD86EFEQ58850257-472f6ee9-4b15-558b-bf43-b693b5fc7286Q59276346-19d2186c-4862-c3fd-da57-665b89729f1fQ59557280-f64bd7c2-40d4-1c7a-d2ff-6394fff09c52Q59668372-441C5E20-52C7-417D-A881-361C43A555F2Q59684881-4ffd0c04-450f-dccd-9a07-84737ba95489Q59749389-4B705380-869A-4437-A939-8458E095003BQ59772546-2B778C48-BC87-4D91-BB4F-9830F6FA3528Q59772548-D268D824-8A8E-407D-A694-EABABB8D4C80Q60392210-10E7A278-3703-4C74-8227-1711B91ED445Q60501328-90765AF2-1DC1-4AD9-8686-044DDF586977Q60501334-8E15233D-7FA1-4277-9542-79B2299F14F5Q60501336-5B88A48B-1A9A-40B8-8C31-202478B24501Q60501340-D6B1DED9-C559-47B9-AB80-D3729321567AQ60502456-7677F4E6-2E43-45EE-A348-02945176AD72Q60502459-E0FD8250-F6DF-4FC7-870C-F6182FA3F5F1Q60502462-1F9A3677-4363-4627-BA58-FE60781F5A0F
P6099
Q21260391-18646A7B-3A9F-42A0-B3F6-7C7EF1DAB472Q21261269-AAD588BF-C541-48F3-9E62-031B3A49F907Q21261279-A7CA32AB-0C52-4536-8765-7EBB7E0A1CE2Q24535495-BD187F4E-0DE0-4900-959A-BCB18EF03F77Q24563045-93FA313D-F449-43B9-8DD1-EF002844D100Q24564715-9C0BB1C4-7F8E-4D43-9094-BE71BC99D0CFQ24601496-B83F1E57-489E-4B41-A513-2F1CF277117FQ24601525-CD77BBB8-B9C3-4C97-9490-BEA0E38D32A0Q24606434-150B3A2A-2337-4EFC-8EC5-71E0F9D22176Q24607479-D5DB9398-E34B-4251-9B12-2EB18F6991E5Q24626194-99DAEF70-0C83-4290-A7E3-C9915C95343DQ24629295-C8E0590A-FD81-495D-A6D7-31FC8BAF9A1AQ24632187-BB45BA6F-086F-481E-B4DF-5BBA52F070D1Q24634360-61B696E1-97C3-4FD4-8FFE-620ACCDF0A8CQ24635643-BA00005B-62AE-46DD-A783-0C7B1B972011Q24644727-591475D8-B0D5-4C2B-8E94-FD3F2180D6DFQ24681480-655B6EFA-71F2-4F92-B0D8-B7AA9CFEF2C5Q24799659-C946377E-3F0F-46A4-8600-719EC9A582CBQ24800647-1A195D7C-98F9-4F08-853C-98249CA17D9AQ24802587-2BC95733-6B55-44C6-830B-B1DA34347467Q24805843-FDC0DD38-198E-43D8-BB96-04150B7DD9B3Q24806469-7364BC15-28DA-4EDC-AFC3-E320A0D89FD3Q24812856-11792EDD-D4C1-4EF5-8761-F824A9BE13EEQ24814067-FB447E09-1FD3-4815-8DF3-1F94F23DB175Q26766584-E21F7503-BE7E-4347-BC58-FC46CDD91C1FQ26774585-9C569BE8-F694-4B83-A983-6FBB6425B446Q26829564-7B0E3069-A3B0-483B-8610-7749EFC8269FQ26849875-893D3DD1-0106-420C-ADF8-17F1D33C9266Q26858884-E1BEC716-8D78-4E67-8D94-2A6F0855E05BQ27012934-9373BB8B-E900-4301-91E3-19A53031D310Q27310843-518E6D86-BE43-4DCA-B736-06FBFF9FF5ACQ27468578-3CD5326F-77FD-46DE-9327-A1A5EA773B25Q27498979-9F3A8FC0-A0D1-44C1-A292-034ADF3FE7B3Q27824805-0DB99068-8A22-405A-8E7C-DBEC92E82987Q27824810-91EA0935-3FB3-4BB6-B5A7-92E5ACDC511FQ27824811-67610259-FB68-488B-82D8-4B911344BD64Q27824835-838F9731-CE71-4146-A47D-F63CE3B9BD30Q27851528-BE8D67D7-9170-474E-9CDD-DC96349458FEQ27851560-ADBE00F2-F1CA-4680-8ED5-CD41034707EFQ27851656-FE2B852E-4FAD-44C6-8633-36324F576212
P921
description
fase intermedia de un ensayo c ...... acia y los efectos secundarios
@es
intermediate phase of a clinical trial, aimed at determining efficacy and side effects
@en
prostřední fáze klinického hodnocení nového léku
@cs
少数の軽症患者を対象に被験薬の有効性や安全性を検討する、治験における段階
@ja
name
Phase-II-Studie
@de
essai clinique phase 2
@fr
fase 2 d'assaig clínic
@ca
fase 2 de ensayo clínico
@es
klinische proeffase II
@nl
phase II clinical trial
@en
studie II. fáze
@cs
фаза II клиничког тестирања
@sr
المرحلة الثانية للتجربة السريرية
@ar
第II相試験
@ja
type
label
Phase-II-Studie
@de
essai clinique phase 2
@fr
fase 2 d'assaig clínic
@ca
fase 2 de ensayo clínico
@es
klinische proeffase II
@nl
phase II clinical trial
@en
studie II. fáze
@cs
фаза II клиничког тестирања
@sr
المرحلة الثانية للتجربة السريرية
@ar
第II相試験
@ja
altLabel
2. fáze klinického hodnocení
@cs
Klinik Phase 2
@de
Klinik Phase II
@de
Phase-2-Studie
@de
clinical trial, phase II
@en
fase II de ensayo clínico
@es
fáze II klinického hodnocení
@cs
phase 2 clinical trial
@en
phase 2 trial
@en
phase 2
@en
prefLabel
Phase-II-Studie
@de
essai clinique phase 2
@fr
fase 2 d'assaig clínic
@ca
fase 2 de ensayo clínico
@es
klinische proeffase II
@nl
phase II clinical trial
@en
studie II. fáze
@cs
фаза II клиничког тестирања
@sr
المرحلة الثانية للتجربة السريرية
@ar
第II相試験
@ja
P672
P279
P3712
P672
E05.318.372.250.250.210
N05.715.360.330.250.250.210
N06.850.520.450.250.250.210
V03.175.250.200